Pfizer Inc. (NYSE:PFE) Shares Acquired by Y.D. More Investments Ltd

Y.D. More Investments Ltd boosted its stake in Pfizer Inc. (NYSE:PFE) by 29.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 33,307 shares of the biopharmaceutical company’s stock after buying an additional 7,602 shares during the quarter. Y.D. More Investments Ltd’s holdings in Pfizer were worth $884,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Hager Investment Management Services LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $43,000. Alexander Labrunerie & CO. Inc. lifted its holdings in Pfizer by 1.5% in the 4th quarter. Alexander Labrunerie & CO. Inc. now owns 45,777 shares of the biopharmaceutical company’s stock valued at $1,214,000 after purchasing an additional 681 shares in the last quarter. Ping Capital Management Inc. boosted its stake in Pfizer by 7.1% during the 4th quarter. Ping Capital Management Inc. now owns 15,000 shares of the biopharmaceutical company’s stock worth $398,000 after purchasing an additional 1,000 shares during the last quarter. Stratos Investment Management LLC boosted its position in Pfizer by 36.9% during the fourth quarter. Stratos Investment Management LLC now owns 20,430 shares of the biopharmaceutical company’s stock worth $542,000 after acquiring an additional 5,502 shares during the last quarter. Finally, Silverlake Wealth Management LLC lifted its stake in Pfizer by 8.4% in the 4th quarter. Silverlake Wealth Management LLC now owns 76,689 shares of the biopharmaceutical company’s stock worth $2,035,000 after purchasing an additional 5,966 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.2 %

Shares of NYSE PFE opened at $25.88 on Wednesday. The stock has a fifty day simple moving average of $26.27 and a 200-day simple moving average of $27.82. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $146.64 billion, a PE ratio of 34.97, a PEG ratio of 0.66 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.65%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Guggenheim cut their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.